The Ministry of Health has updated the rules for evaluating medicinal products: what will change for patients

The Ministry of Health of Ukraine has updated the Guidelines for the State Assessment of Medical Technologies (SAT) for medicinal products. One of the key innovations was the introduction of an assessment of the level of added clinical benefit, which will allow for a more effective determination of which drugs and medical technologies really provide better treatment results.

This was reported by the State Expert Center of the Ministry of Health of Ukraine.

From now on, when assessing medicinal products, not only their effectiveness will be taken into account, but also their additional clinical value compared to existing treatment methods.

The assessment will be carried out according to several criteria, including:

the clinical significance of the results for the health of patients;

the magnitude of the relative therapeutic effect;

the safety profile of the drug;

the quality of the evidence base;

the level of unmet medical need.

The Ministry of Health notes that the new approach will help direct state funding primarily to those medical technologies that provide the greatest benefit to patients and have proven clinical effectiveness.

In addition, the updated Guidelines bring the Ukrainian system of medical technology assessment closer to European standards, which should make the decision-making process more transparent, justified and effective.

The relevant changes were approved by the Order of the Ministry of Health of Ukraine dated July 23, 2026 No. 1011.